Litcius/Paper detail

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

Li Xuan, Yu Wang, Fen Huang, Zhiping Fan, Yajing Xu, Jing Sun, Na Xu, Lan Deng, Xudong Li, Xinquan Liang, Xiaodan Luo, Pengcheng Shi, Hui Liu, Zhixiang Wang, Ling Jiang, Chunzi Yu, Xuan Zhou, Ren Lin, Yan Chen, Sanfang Tu, Xiao‐Jun Huang, Qifa Liu

2020The Lancet Oncology313 citationsDOI

Topics & Concepts

MedicineTransplantationSorafenibCumulative incidenceInternal medicineClinical endpointTolerabilityHazard ratioPopulationOncologyHematopoietic stem cell transplantationAdverse effectSurgeryClinical trialConfidence intervalHepatocellular carcinomaEnvironmental healthAcute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsHematopoietic Stem Cell Transplantation
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial | Litcius